Reumatizam, Vol. 53 No. 2, 2006.
Izlaganje sa skupa
Ibandronate
Đurđica Babić-Naglić
; Klinika za reumatske bolesti i rehabilitaciju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
Simeon Grazio
; Klinika za reumatologiju, fizikalnu medicinu i rehabilitaciju, Klinička bolnica “Sestre milosrdnice”, Zagreb, Hrvatska
Sažetak
Osteoporosis is chronic bone disorder that require persistent treatment. Bone fracture is the final outcome of OP and early diagnosis, active prevention, treatment and improvement of the patient adherence to treatment are needed. Ibandronate is a potent, nitrogen-containing bisphosphonate specifically developed for once-monthly oral and three-monthly administration with the same anti-resorptive efficacy. Ibandronate reduce vertebral fracture risk 50-60%, increase spine and hip BMD, 6% and 3%, significantly decrease biochemical markers of bone turnover without histomorphometric changes of bone. There is strong patient preference for once-monthly regimen and the favourable impact on therapeutic adherence. Intravenous ibandronate formulation is indicated for all patients who are unable to take oral medicine. Adverse events are infrequent, short duration and reversibile.
Ključne riječi
adherence; ibandronate; osteoporosis
Hrčak ID:
125834
URI
Datum izdavanja:
20.10.2006.
Posjeta: 892 *